DK1202746T3 - NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer - Google Patents

NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer

Info

Publication number
DK1202746T3
DK1202746T3 DK00950930T DK00950930T DK1202746T3 DK 1202746 T3 DK1202746 T3 DK 1202746T3 DK 00950930 T DK00950930 T DK 00950930T DK 00950930 T DK00950930 T DK 00950930T DK 1202746 T3 DK1202746 T3 DK 1202746T3
Authority
DK
Denmark
Prior art keywords
nsaid
inhibition
treatment
colorectal cancer
kinase inhibitor
Prior art date
Application number
DK00950930T
Other languages
Danish (da)
English (en)
Inventor
Philip Frost
Carolyn Mary Discafani-Marro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1202746T3 publication Critical patent/DK1202746T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00950930T 1999-08-12 2000-08-02 NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer DK1202746T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12

Publications (1)

Publication Number Publication Date
DK1202746T3 true DK1202746T3 (da) 2007-01-02

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00950930T DK1202746T3 (da) 1999-08-12 2000-08-02 NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer

Country Status (24)

Country Link
EP (1) EP1202746B1 (https=)
JP (1) JP2003507342A (https=)
KR (1) KR20020018201A (https=)
CN (1) CN1229142C (https=)
AR (1) AR029763A1 (https=)
AT (1) ATE341341T1 (https=)
AU (1) AU783116B2 (https=)
BR (1) BR0013219A (https=)
CA (1) CA2380904C (https=)
CZ (1) CZ2002474A3 (https=)
DE (1) DE60031127T2 (https=)
DK (1) DK1202746T3 (https=)
EA (1) EA006876B1 (https=)
ES (1) ES2272305T3 (https=)
HK (1) HK1042244A1 (https=)
HU (1) HUP0203162A3 (https=)
IL (1) IL147913A0 (https=)
MX (1) MXPA02001448A (https=)
NO (1) NO20020663L (https=)
NZ (1) NZ517120A (https=)
PL (1) PL353267A1 (https=)
PT (1) PT1202746E (https=)
WO (1) WO2001012227A1 (https=)
ZA (1) ZA200201156B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
CN1190197C (zh) * 2000-03-13 2005-02-23 惠氏控股公司 氰基喹啉用于制备治疗或抑制结肠息肉药物中的用途
EP1412367A4 (en) 2001-06-21 2006-05-03 Ariad Pharma Inc NEW CHINOLINE AND ITS USE
WO2003008409A1 (en) 2001-07-16 2003-01-30 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
US20050043409A1 (en) * 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60313339T2 (de) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
RU2006146612A (ru) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
PL387312A1 (pl) 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
CA2837227C (en) * 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135900A0 (en) * 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
BR9814116A (pt) * 1997-11-06 2000-10-03 American Cyanamid Co Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico

Also Published As

Publication number Publication date
DE60031127T2 (de) 2007-02-01
EP1202746A1 (en) 2002-05-08
DE60031127D1 (de) 2006-11-16
HUP0203162A3 (en) 2006-07-28
EA200200246A1 (ru) 2002-08-29
MXPA02001448A (es) 2002-07-02
HK1042244A1 (zh) 2002-08-09
AR029763A1 (es) 2003-07-16
HUP0203162A2 (hu) 2003-01-28
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
BR0013219A (pt) 2002-04-23
KR20020018201A (ko) 2002-03-07
EP1202746B1 (en) 2006-10-04
NO20020663D0 (no) 2002-02-11
ZA200201156B (en) 2003-05-12
CA2380904C (en) 2009-02-10
JP2003507342A (ja) 2003-02-25
EA006876B1 (ru) 2006-04-28
PL353267A1 (en) 2003-11-03
CN1370080A (zh) 2002-09-18
IL147913A0 (en) 2002-08-14
PT1202746E (pt) 2007-01-31
ATE341341T1 (de) 2006-10-15
ES2272305T3 (es) 2007-05-01
WO2001012227A1 (en) 2001-02-22
AU6395900A (en) 2001-03-13
NO20020663L (no) 2002-04-09
NZ517120A (en) 2004-10-29
CZ2002474A3 (cs) 2003-02-12
CN1229142C (zh) 2005-11-30

Similar Documents

Publication Publication Date Title
DK1202746T3 (da) NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
NO20002166D0 (no) Anvendelse av quinazolinderivater som tyrosinkinaseinhibitorer for behandling av kolonpolypper
DK1263503T3 (da) Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
IS2468B (is) Aðferðir og milliefni til framleiðslu á efnasamböndum gegn krabbameini
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
IS7233A (is) Kínasólín afleiður til meðhöndlunar á afbrigðilegum frumuvexti
DK1165078T3 (da) Fremgangsmåder til induktion af cancercelledöd og tumorregression
NO20021820L (no) Tyrosinkinaseinhibitorer
DK1576132T3 (da) Nukleinsyrer benævnt 273p4b7 og anvendelse heraf til detektering af cancer
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
NO20012583D0 (no) Quinoliner og quinoksalinforbindelser som PDGF-R- og/eller LCK-tyrosinkinase-inhibitorer
ATE412070T1 (de) Prognose von kolorektalem krebs
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
DK1212317T3 (da) Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
IS5772A (is) Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum
NO20022245L (no) Onkolyttiske kombinasjoner for behandling av cancer
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
DK1694364T3 (da) System til behandling og forebyggelse af brystcancer
NO20034350D0 (no) Optisk avbilding av kolorektal kreft
AU2002311859A1 (en) Compositions and methods for treating colorectal polyps and cancer
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer